Business Standard

Tuesday, December 24, 2024 | 06:40 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zuventus first in world to launch aviptadil for ARDS commercially

Discovered in 1970, the drug was tested on severe Covid-19 patients on DCGI's direction

Medicines, Pharma
Premium

Aviptadil was discovered by Dr Sami Said, pulmonary medicine specialist, in 1970

Sohini Das Mumbai
Mumbai-based Zuventus Healthcare has become the first company globally to commercially launch aviptadil, over 50-year old drug molecule, for treating acute respiratory distress syndrome (ARDS).

The drug was discovered by Dr Sami Said, pulmonary medicine specialist, in 1970. Aviptadil -- a complex peptide -- was not commercially used for ARDS, though prescribed as a last resort (orphan drug); it is prepared by Universities for emergency use by hospitals, the company said.

The use of aviptadil (a vasoactive intestinal peptide) restores respiration and reduces mortality in patients with ARDS. “Aviptadil is safe and effective in tackling respiratory failure, shortens recovery time,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in